Efficacy of pneumococcal conjugate vaccines in large scale field trials

Pediatric Infectious Disease Journal

Volumn 19, Issue 4, 2000, Pages 394-397

  Shinefield, Henry R ^a   Black, Steve ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Clinical trials; Conjugate vaccines; Pneumococcal vaccines

Indexed keywords

DIPHTHERIA TOXIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; OTITIS MEDIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; BACTERIAL VACCINES; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; FINLAND; HUMANS; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PROGNOSIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0033996108     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200004000-00036     Document Type: Review

References (29)

1. Poland GA. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 1999;17:1674-9.
2. Torzillo PJ. Pneumococcal vaccine. Aust Fam Physician 1997; 26:937-41.
3. Eskola J, Takala AK, Kilpi TM, Lankinen KS, Kayhty H. Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Dev Biol Stand 1998;95:85-92.
4. World Health Organization. Programme for the control of acute respiratory infections: pneumococcal conjugate vaccines: Report WHO/ARI/94.34. In: WHO Meeting, Geneva, Switzerland, 1994.
5. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci 1999;354:777-85.
6. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-8):1-24.
7. Hess T. [Pneumococcal vaccination: yes or no?] Schweiz Med Wochenschr 1998;128:1096-103.
8. Flo RW, Solberg CO. [Pneumococcal vaccine.] Tidsskr Nor Laegeforen 1998;118:3799-802.
9. McIntyre P. Epidemiology and prevention of pneumococcal infections. Curr Opin Pediatr 1997;9:9-13.
10. Bruyn GA, van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis 1991;10:897-910.
11. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children: implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
12. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(Suppl 1):S49-52.
13. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-16.
14. Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15: 134-9.
15. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101:604-11.
16. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-53.
17. Sigurdardottir ST, Vidarsson G, Gudnason T, et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997;16:667-74.
18. Shinefield HR, Black S, Ray P, Chang IH, et al. Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-63.
19. King JC Jr, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998;16:361-5.
20. Obaro SK, Huo Z, Banya WA, et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
21. O'Brien KL, Steinhoff MC, Edwards K, Keyserling H, Thorns ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996;15:425-30.
22. Anttila M, Eskola J, Ahman H, Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17: 1970-7.
23. Vidarsson G, Sigurdardottir ST, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66: 2866-70.
24. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
25. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.
26. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
27. Klein JO. Otitis media. Clin Infect Dis 1994;19:823-33.
28. Berman S. Otitis media in children. N Engl J Med 1995;332: 1560-5.
29. Bulla A, Hitze KL. Acute respiratory infections: a review. Bull World Health Organ 1978;56:481-98.